Logo
Lipo Lax Bundle (Lipo Lax+ & Lipo Lax VL)

Lipo Lax Bundle (Lipo Lax+ & Lipo Lax VL)

Lipo Lax

Fat Dissolver
  • Manufactured in South Korea by Koru Pharma in facilities operating under recognised quality standards for aesthetic and cosmetic injectables.
  • Marketed internationally as professional Use injectable lipolytic solutions; regulatory classification and approval status vary by country.
  • Not listed as a UK MHRA Authorised medicine or medical device for fat reduction; must be used only where legally permitted and within the prescriber’s scope of practice.
  • Use restricted to qualified professionals in accordance with local health, safety and advertising regulations for aesthetic treatments.
Body and Facial Fat-Dissolving Injection Bundle

Description

The Lipo-Lax Bundle combines two complementary Korean lipolytic mesotherapy products: Lipo Lax+ for body lipolysis and Lipo Lax VL for facial mesocorrection. Lipo Lax+ is formulated with high-dose phosphatidylcholine, deoxycholate, purified PPC and L-carnitine to dissolve localised body fat, reduce cellulite and improve tissue firmness. Lipo Lax VL is a peptide-enriched facial lipolytic solution designed to reduce local fat deposits in areas such as the chin, cheeks and jawline while simultaneously tightening and rejuvenating the skin. Sold together, this bundle provides a complete non-surgical fat-dissolving and contouring solution for both body and face when used by trained professionals.

Bnefits

  • Convenient combined pack providing both body (Lipo Lax+) and facial (Lipo Lax VL) fat-dissolving solutions in a single bundle.
  • Allows targeted treatment of larger body areas (abdomen, flanks, thighs, hips, arms, back) and delicate facial zones (cheeks, double chin, jawline, nasolabial folds).
  • Lipo Lax+ rapidly dissolves localised body fat and cellulite using high-purity PPC and deoxycholate while supporting fat metabolism with L-carnitine.
  • Lipo Lax VL reduces facial fat deposits and simultaneously tightens, lifts and rejuvenates skin through biomimetic peptides and L-carnitine.
  • Both formulas promote improvement of skin elasticity, tone and texture during fat-reduction therapy.
  • Non-surgical alternative to liposuction with comparatively minimal downtime when protocols are followed correctly.
  • Formulas developed using modern pharmacology and biotechnology to deliver noticeable contouring results typically within a short treatment course.
  • Manufactured in South Korea with active substances of high purity sourced from reputable international suppliers.

Indications

  • Professional injection lipolysis for localised subcutaneous fat deposits on the body (with Lipo Lax+).
  • Body contouring and circumference reduction in areas such as abdomen, side folds (love handles), hips, buttocks, inner and outer thighs, knees, upper arms, back and subscapular regions.
  • Reduction and smoothing of cellulite and skin laxity in selected body sites.
  • Facial mesocorrection of local fat deposits using Lipo Lax VL (e.g. cheeks, ears area, double chin, jawline, nasolabial folds, lower face contour).
  • Improvement of facial skin tension, elasticity and contour along the V-line.
  • Adjunctive treatment for adult patients seeking non-surgical slimming and contouring of both face and body where diet and exercise alone are insufficient.

Composition

  • Lipo Lax+ (body lipolytic):
  • • Phosphatidylcholine (PPC) 1000 mg per 10 ml – high-purity PPC (~99.8%) acting as the main lipolytic agent to disrupt adipocyte membranes and emulsify fat.
  • • Sodium deoxycholate 5 mg per 10 ml – bile acid salt (~98% purity) that dissolves fat cell membranes and aids emulsification.
  • • Purified PPC (German-origin raw material, ~99.8% purity).
  • • L-carnitine 200 mg – supports transport of fatty acids into mitochondria and enhances fat metabolism.
  • • Peptide / biorevitalising cocktail – combination of peptides and skin-supporting actives (exact breakdown proprietary) that helps improve firmness and tissue quality.
  • • Solvent system, water for injection and excipients (including preservatives such as benzyl alcohol and parabens as listed on the original packaging).
  • Lipo Lax VL (facial lipolytic):
  • • Phosphatidylcholine – main lipolytic component responsible for adipocyte lysis and mobilisation of fatty acids.
  • • L-carnitine – conductor of fatty acids into mitochondria, supports lipolysis and skin nourishment.
  • • Acetyl-hexapeptide-8 ("botox peptide") – peptide that reduces the appearance of expression lines by limiting certain nerve impulses and relaxing facial muscles.
  • • Palmitoyl pentapeptide-4 – peptide that stimulates cellular regeneration, neocollagenesis and elastin production.
  • • Palmitoyl tetrapeptide-7 – peptide supporting dermal restructuring, collagen synthesis and anti-inflammatory activity.
  • • Sodium hyaluronate – hydrating component that improves skin moisture and elasticity.
  • • Additional vitamins, amino acids and excipients as listed in the Lipo Lax VL product documentation.

Formulation

  • Bundle of two sterile injectable lipolytic solutions:
  • • Lipo Lax+ – body lipolytic mesotherapy solution containing high-dose PPC and deoxycholate with L-carnitine and peptide complex; designed for subcutaneous injection into localised body fat deposits.
  • • Lipo Lax VL – facial lipolytic mesotherapy solution enriched with PPC, L-carnitine and biomimetic peptides for mesocorrection of local fat and lifting of facial contours.
  • Both products are sterile cosmetic / aesthetic formulations for professional use only, manufactured as clear or slightly opalescent injectable solutions.
  • Developed using advanced pharmacology and biotechnology to deliver strong lipolytic action with simultaneous skin-tightening and rejuvenation effects.
  • Non-animal sourced ingredients; phosphatidylcholine typically derived from purified soybean lecithin.
  • Formulations intended for use in adults (18+) under appropriate clinical supervision.

Packaging

  • The Lipo-Lax Bundle typically contains:
  • • Lipo Lax+ – 1 box (10 vials × 10 ml) body lipolytic solution.
  • • Lipo Lax VL – 1 box (10 vials × 10 ml) facial lipolytic solution.
  • Vials are glass with rubber stoppers and sealed caps, labelled for professional use.
  • Outer packaging includes branding, product names, batch numbers, expiry dates and manufacturer/importer details.
  • Bundle is sold by The Crystal Pharmacy and partner platforms as a combined fat-dissolving package for face and body.
  • Packaging and exact configuration may vary slightly by distributor (some may also offer single-vial options for each product outside the bundle).

Usage

  • For professional use only; both Lipo Lax+ and Lipo Lax VL must be administered by suitably trained and licensed medical or aesthetic practitioners.
  • Lipo Lax+ (body):
  • • Inject into the subcutaneous fat layer in localised body areas; avoid intradermal and intramuscular injection.
  • • Use small volumes per injection point (e.g. around 0.05–0.2 ml per point depending on area and depth), distributed evenly with points spaced roughly 1–1.5 cm apart.
  • • Common treatment protocol: 1 session every 14–21 days, with a course of approximately 3 (up to 6 or more) sessions depending on the thickness of fat and desired results.
  • • Maximum total dose per treatment is typically limited (e.g. up to about 30 ml across all treated areas) according to product guidance and clinical judgement.
  • • Focus injections strictly on fat deposits, not on surrounding non-adipose tissues.
  • Lipo Lax VL (face):
  • • Used for mesocorrection of local fat deposits on the face (cheeks, ears region, chin, nasolabial folds, jawline).
  • • Depth of injection generally 0.2–0.5 cm (superficial subcutaneous layer) using a fine needle (e.g. 30G) or mesotherapy technique; avoid intradermal and intramuscular placement.
  • • Single treatment often comprises multiple 0.3 ml injections up to a total of around 10 ml per session, spaced approximately 1 cm apart, according to distributor protocols.
  • • Up to 3 treatments may be administered with intervals of at least 14 days between sessions for facial protocols.
  • General guidance (both products):
  • • Assess patient suitability carefully; take full medical history and rule out contraindications before treatment.
  • • Disinfect the treatment area thoroughly and use strict aseptic technique, sterile equipment and appropriate sharps disposal.
  • • Do not mix these solutions in the same syringe with other injectable products unless explicitly stated as safe by the manufacturer.
  • • Advise patients of expected post-treatment effects (swelling, redness, tenderness, bruising) and provide written aftercare.
  • • Typical aftercare includes avoiding hot baths, saunas, high-intensity exercise and alcohol for 24–48 hours and maintaining adequate hydration.
  • • Monitor for any unusual pain, significant asymmetry, prolonged swelling or other adverse events and manage promptly in line with complication protocols.

Contraindications

  • Known hypersensitivity or allergy to phosphatidylcholine, soy-derived products, sodium/deoxycholate, L-carnitine, peptides, sodium hyaluronate or any other component of Lipo Lax+ or Lipo Lax VL.
  • Pregnancy or breastfeeding.
  • Active skin disease, infection, inflammation, eczema or open wounds at or near the intended treatment area.
  • Severe or uncontrolled systemic diseases (e.g. significant hepatic, renal, cardiac or metabolic disorders) without prior medical clearance.
  • Bleeding disorders or concurrent use of strong anticoagulant or antiplatelet medications without thorough risk assessment.
  • History of severe allergic reactions, anaphylaxis or serious adverse events to injectable treatments.
  • Autoimmune or immunosuppressive conditions unless carefully evaluated and approved by a physician.
  • Use in patients under 18 years of age unless specifically allowed by local regulations and under specialist supervision.
  • General obesity requiring systemic management rather than localised lipolysis alone; not a substitute for comprehensive weight-loss strategies.
  • Any further contraindications or cautions listed in the official Lipo Lax+ and Lipo Lax VL instructions for use or local clinical guidelines.

Adverse Effects

  • Common transient effects for both Lipo Lax+ and Lipo Lax VL include redness, warmth, swelling and tenderness at injection sites.
  • Bruising, local discomfort or burning sensation during and after injection, usually resolving within a few days.
  • Temporary induration, nodules or lumpiness in the treated area as fat breaks down and tissues remodel.
  • Mild itching, tingling or increased sensitivity in the treated region.
  • Short-term feeling of heaviness, tightness or fullness in the treated area.
  • Occasional asymmetry or uneven contouring that may require further treatment or corrective procedures.
  • Rare but more serious complications such as infection, pronounced inflammatory reactions, allergic or hypersensitivity responses, nerve irritation or damage, or very rarely skin necrosis or scarring; these require prompt medical assessment and management.
  • Systemic reactions are uncommon but can include malaise or mild flu-like symptoms due to inflammatory and metabolic responses to lipolysis in susceptible individuals.

Storage Conditions

  • Store both Lipo Lax+ and Lipo Lax VL in a cool, dry place away from direct sunlight and heat sources, according to the temperature range stated on the packaging (typically controlled room temperature).
  • Do not freeze the products.
  • Keep vials in their original cartons until use to protect from light and contamination.
  • Ensure vials are not used after the expiry date printed on the packaging.
  • Discard any vial that is cracked, leaking, discoloured or contains visible particulate matter.
  • Once opened, if any solution remains and local rules allow, it should be handled according to the manufacturer’s recommendations for reuse (often single-use only) or disposed of as clinical waste.
  • Keep out of reach of children.
  • Store in accordance with general clinic protocols for injectable aesthetic products and relevant local regulations.

Duration

For Lipo Lax+ and Lipo Lax VL, treatment protocols commonly involve one session every 14\u201321 days over a period of approximately 3\u20136 months. Many patients see noticeable improvements after around 3 sessions, with further refinement possible if additional sessions are performed. Reduction in fat cells is considered long-lasting or permanent in treated areas when a stable body weight and healthy lifestyle are maintained, although new fat accumulation is still possible.

Onset

Biochemical lipolysis starts soon after injection. Clinically visible improvements in contour usually appear progressively over 2\u20134 weeks following each session, with more pronounced body and facial sculpting results after completion of the recommended course. Skin-tightening and rejuvenation effects from the peptide components of Lipo Lax VL may continue to develop for several weeks as collagen and elastin are remodelled.

Browse more Fat Dissolver

Top Treatments

Top Cities in the UK